Dissecting the biological heterogeneity of HER2-positive breast cancer.

Breast · 2021 · PMC8374722 · PMID 34392185

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, the randomized phase II KATE-2 showed a trend for a PFS benefit in pretreated HER2+ PDL1+ tumors with T-DM1 and the anti-PD-L1 atezolizumab, with no benefit for the overall population enrolled, or in the PD-L1-negative subset [ 83 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.